Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ALW-II-41-27
i
Other names:
ALW-II-41-27
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
University of Naples Federico II
Drug class:
EphA2 receptor antagonist
Related drugs:
‹
dasatinib (215)
BCY6033 (1)
BT5528 (0)
BT7455 (0)
GLPG 1790 (0)
SL-701 (0)
MM-310 (0)
dasatinib (215)
BCY6033 (1)
BT5528 (0)
BT7455 (0)
GLPG 1790 (0)
SL-701 (0)
MM-310 (0)
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
RET C634R
Thyroid Gland Carcinoma
RET C634R
Thyroid Gland Carcinoma
ALW-II-41-27
Sensitive: D – Preclinical
ALW-II-41-27
Sensitive
:
D
ALW-II-41-27
Sensitive: D – Preclinical
ALW-II-41-27
Sensitive
:
D
RET M918T
Thyroid Gland Carcinoma
RET M918T
Thyroid Gland Carcinoma
ALW-II-41-27
Sensitive: D – Preclinical
ALW-II-41-27
Sensitive
:
D
ALW-II-41-27
Sensitive: D – Preclinical
ALW-II-41-27
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login